Brief: BioXcel Therapeutics Q2 Basic EPS USD -2.45 Vs. IBES Estimate USD -1.86
12/08/2025 12:55
Aug 12 (Reuters) - BioXcel Therapeutics Q2 operating expenses USD 15.972 million. Q2 net income USD -19.187 million vs. IBES estimate USD -12.8 million Q2 operating income USD -15.852 million vs. IBES estimate USD -9.9 million Q2 revenue USD 120 thousand vs. IBES estimate USD 250 thousand
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty